Author | Year | No. of patients randomized | No. of patients receiving intervention | No. of patients receiving comparison | Trial duration (weeks) | Intervention | Comparator | Risk of bias* selection/performance/attrition/reporting |
---|---|---|---|---|---|---|---|---|
Dougados | 1986 | 30 | 15 | 15 | 26 | SSZ (P) | PL | A/A/A/A |
Feltelius | 1986 | 37 | 18 | 19 | 12 | SSZ (P) | PL | U/U/A/A |
Nissila | 1988 | 85 | 43 | 42 | 26 | SSZ (P) | PL | U/U/A/A |
Davis | 1989 | 30 | 15 | 15 | 12 | SSZ (P) | PL | U/U/A/A |
Kraag | 1989 | 53 | 26 | 27 | 16 | Supervised training (NP) | SC | U/U/I/A |
Winkler | 1989 | 63 | 31 | 32 | 24 | SSZ (P) | PL | U/U/U/A |
Corkill | 1990 | 62 | 32 | 30 | 48 | SSZ (P) | PL | A/A/I/A |
Krajnc | 1990 | 95 | 71 | 24 | 24 | SSZ (P) | PL | U/U/A/A |
Taylor | 1991 | 40 | 20 | 20 | 52 | SSZ (P) | PL | A/A/A/I |
Hidding | 1993 | 144 | 68 | 76 | 36 | Group physiotherapy (NP) | AC | A/A/I/A |
Kirwan | 1993 | 89 | 44 | 45 | 156 | SSZ (P) | PL | A/A/A/I |
Dougados | 1994 | 70 | 46 | 24 | 12 | Ximoprofen 5 mg (P) | PL | A/A/U/A |
1994 | 73 | 49 | 24 | 34 | Ximoprofen 10 mg (P) | PL | A/A/U/A | |
1994 | 69 | 45 | 24 | 8 | Ximoprofen 20 mg (P) | PL | A/A/U/A | |
1994 | 74 | 50 | 24 | 6 | Ximoprofen 30 mg (P) | PL | A/A/U/A | |
Clegg | 1996 | 264 | 131 | 133 | 36 | SSZ (P) | PL | U/U/A/A |
Helliwell | 1996 | 22 | 15 | 7 | 44 | In-patient physiotherapy (NP) | SC | I/I/I/A |
1996 | 22 | 15 | 7 | 44 | Out-patient hydrotherapy (NP) | SC | I/I/I/A | |
Dougados | 1999 | 148 | 108 | 40 | 6 | Piroxicam (P) | PL | U/U/A/A |
1999 | 160 | 120 | 40 | 6 | Meloxicam 15 mg (P) | PL | U/U/A/A | |
1999 | 164 | 124 | 40 | 6 | Meloxicam 22.5 mg (P) | PL | U/U/A/A | |
Altan | 2001 | 51 | 26 | 25 | 52 | MTX (P) | AC | U/U/I/I |
Dougados | 2001 | 118 | 80 | 38 | 6 | Celecoxib (P) | PL | U/U/U/A |
2001 | 128 | 90 | 38 | 6 | Ketoprofen (P) | PL | U/U/U/A | |
Van Tubergen | 2001 | 120 | 80 | 40 | 3 | Spa-exercise therapy (NP) | AC | A/A/I/A |
Braun | 2002 | 70 | 35 | 35 | 12 | Infliximab (B) | PL | A/A/A/I |
Gorman | 2002 | 40 | 20 | 20 | 16 | Etanercept (B) | PL | A/A/A/A |
Roychowdhury | 2002 | 30 | 14 | 16 | 24 | MTX (P) | PL | U/U/A/A |
Schmidt | 2002 | 70 | 34 | 36 | 26 | SSZ (P) | PL | U/U/U/A |
Sweeney | 2002 | 200 | 100 | 100 | 26 | Supervised training (NP) | SC | U/U/I/A |
Analay | 2003 | 51 | 27 | 24 | 12 | Supervised training (NP) | SC | A/A/I/A |
Brandt | 2003 | 33 | 16 | 17 | 6 | Etanercept (B) | PL | A/A/A/I |
Davis | 2003 | 277 | 138 | 139 | 24 | Etanercept (B) | PL | A/A/A/A |
Calin | 2004 | 84 | 45 | 39 | 12 | Etanercept (B) | PL | U/U/A/A |
Gonzalez-Lopez | 2004 | 35 | 17 | 18 | 24 | MTX (P) | PL | A/A/A/I |
Codish | 2005 | 28 | 14 | 14 | 12 | Balneo therapy (NP) | AC | U/U/I/A |
D’Las Penas | 2005 | 40 | 20 | 20 | 16 | Supervised training (NP) | SC | A/A/I/A |
Lim | 2005 | 50 | 25 | 25 | 8 | Supervised training (NP) | SC | U/U/I/A |
Marzo-Ortega | 2005 | 42 | 28 | 14 | 30 | Infliximab (B) | PL | A/A/U/A |
Van der Heijde | 2005 | 279 | 201 | 78 | 24 | Infliximab (B) | PL | U/U/A/A |
Van der Heijde | 2005 | 134 | 103 | 31 | 6 | Etoricoxib (P) | PL | A/A/A/A |
2005 | 123 | 92 | 31 | 6 | Etoricoxib (P) | PL | A/A/A/A | |
2005 | 130 | 99 | 31 | 6 | Naproxen (P) | PL | A/A/A/A | |
Altan | 2006 | 60 | 30 | 30 | 24 | Balneo therapy (NP) | AC | U/U/I/A |
Barkhuizen | 2006 | 189 | 137 | 52 | 12 | Celecoxib 200 mg (P) | PL | U/U/U/A |
2006 | 213 | 161 | 52 | 12 | Celecoxib 400 mg (P) | PL | U/U/U/A | |
2006 | 209 | 157 | 52 | 12 | Naproxen (P) | PL | U/U/U/A | |
Ince | 2006 | 30 | 15 | 15 | 12 | Supervised training (NP) | SC | U/U/I/A |
Van der Heijde | 2006 | 315 | 208 | 107 | 24 | Adalimumab (B) | PL | A/A/A/A |
Van der Heijde | 2006 | 180 | 155 | 25 | 24 | Etanercept (B) | PL | U/U/U/A |
2006 | 175 | 150 | 25 | 24 | Etanercept (B) | PL | U/U/U/A | |
Lambert | 2007 | 82 | 38 | 44 | 24 | Adalimumab (B) | PL | U/U/A/A |
Huang | 2008 | 126 | 83 | 43 | 8 | Etanercept (B) | PL | U/U/U/U |
Inman | 2008 | 177 | 138 | 39 | 14 | Golimumab (B) | PL | A/A/A/A |
2008 | 179 | 149 | 39 | 14 | Golimumab (B) | PL | A/A/A/A | |
Barkham | 2010 | 40 | 20 | 20 | 12 | Etanercept (B) | PL | U/U/A/A |
Inman | 2010 | 76 | 39 | 37 | 12 | Infliximab (B) | PL | U/U/U/A |
Braun | 2011 | 566 | 379 | 187 | 16 | Etanercept (B) | AC | A/A/A/A |
Dougados | 2011 | 82 | 39 | 43 | 12 | Etanercept (B) | PL | U/U/A/I |
Navarro-Sarabia | 2011 | 108 | 54 | 54 | 12 | Etanercept (B) | AC | A/A/A/A |
Hu | 2012 | 46 | 26 | 20 | 12 | Adalimumab (B) | PL | U/U/U/I |
Bao | 2014 | 213 | 108 | 105 | 24 | Golimumab (B) | PL | U/U/U/A |
Huang | 2014 | 344 | 229 | 114 | 12 | Adalimumab (B) | PL | A/A/A/A |